fbpx

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Multiple Myeloma Prognosis- Circulating Plasma Cells (CPC)

Share Button

Circulating Plasma Cells (CPC) in Multiple Myeloma (MM) Patients at diagnosis indicate Cytogenetic Abnormalities as well as Poorer Overall Survival 

No one wants to hear the words “you have multiple myeloma.” However, while those two words indicate that you have an incurable blood cancer, your MM prognosis is better than ever with the sophisticated diagnostic testing available today.

If you have been diagnosed with multiple myeloma it is important for you to know that there is a long and growing list of both conventional (FDA approved) and evidence-based, non-conventional therapies for you to use.

I am both a MM survivor and MM cancer coach. My intent is not to raise false hope by writing this blog post. Please understand that the average five-year survival rate for myeloma in 2018 is 49%. But also understand that since my diagnosis in early 1994 I have known dozens of MMers who have lived 10,15, 20 years or more.

Image result for image of circulating plasma cells

The two articles linked and excerpted below discuss a prognostic indicator called circulating plasma cells (CPC).

Your job as a newly diagnosed MMer is to learn as much as you possibly can about your diagnosis. The presence of CPC’s relative to your MM prognosis are another possible indicator of disease aggressiveness.

The more you know about your MM prognosis now the better your decision-making will be about your therapies going forward.

My point is that if you are considering an ASCT then you should also know what, if any, presence of CPC’s you have and what they mean about your MM prognosis.

Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.

Please scroll down the page, post a question or comment and I will reply to you ASAP.

Thanks and hang in there,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis

“The clinical significance and prognostic role of circulating plasma cells (CPCs) in multiple myeloma (MM) are still controversial…

11 studies covering a total of 2943 patients were included. Pooled hazard ratios (HRs) revealed that the presence of CPCs predicted aggressive disease progression

In conclusion, our meta-analysis indicates that the presence of CPCs was associated with aggressive disease course and poor OS in MM patients. CPCs status was strongly associated with elevated ISS stage and represents aggressive disease rather than tumor burden. Regardless of whether CPCs are detected in an early stage or in relapse patients, CPCs status may serve as a useful tool to guide the prognosis of MM patients. Considering the limitations of present analysis, further prospective multicentre studies designed with larger sample size and unified detection methods are needed.

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era

“The impact of circulating plasma cells (CPCs) prior to autologous stem cell transplantation (ASCT) for multiple myeloma has not been defined in the novel agent era.

We evaluated the impact of pre-transplant CPCs, detected by six-color flow cytometry in patients undergoing early ASCT on post-transplant response, progression-free survival (PFS) and overall survival (OS).

CPCs were detected in 162 out of 840 (19.3%) patients, with the median number of CPCs being 58 per 150 000 events. Ninety-nine percent of patients had received proteasome inhibitor and/or immunomodulator-based induction.

The incidence of post-transplant stringent complete response (sCR) in the subgroups with and without CPCs was 15% and 38%, respectively, (P<0.001). The median PFS in the subgroups with and without CPCs was 15.1 (95% confidence interval (CI), 12.5–17.8) and 29.6 months (95% CI, 26.2–32.8), respectively, and the median OS was 41.0 months (95% CI, 32.6–58.2) and not reached (NR) (95% CI, 99.1-NR), respectively, (P<0.001 for both).

On multivariate analysis for OS, factors independently predictive of mortality were the presence of CPCs (hazard ratio (HR) 2.5; 95% CI, 1.8–3.6; P<0.001) and sCR post transplant (HR 0.4; 95% CI, 0.2–0.6; P<0.001). Presence of CPCs prior to transplant has a high prognostic impact and should be prospectively validated in clinical trials.”

 

Leave a Comment:

12 comments
Add Your Reply